GlassScriptPhysician profile
Ian C Boykin
NPI 1891772596
$13,847.79
in general payments reported to CMS, 2019-2025
54 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $1,888 · 2021: $1,991 · 2022: $1,871 · 2023: $2,075 · 2024: $1,708 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,774.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,502.40 | 2019-2025 | |
| Novo Nordisk INC | $1,344.82 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,167.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,072.16 | 2019-2025 | Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $733.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $680.12 | 2021-2025 | |
| Abbvie INC. | $664.85 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astellas Pharma US INC | $503.94 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.71 | 2019-2025 | Stiolto Respimat |
| Glaxosmithkline, LLC. | $458.27 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $425.06 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $422.62 | 2019-2023 | Livalo, Seglentis |
| Abbott Laboratories | $412.04 | 2021-2025 | Aveir, Freestyle Libre 3, Eterna |
| Janssen Pharmaceuticals, INC | $394.21 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $367.99 | 2019-2021 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.66 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $257.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $251.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $179.58 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $156.92 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $142.82 | 2019-2023 | Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $142.25 | 2020-2023 | Nexletol |
| Janssen Biotech, INC. | $125.01 | 2023 | Carvykti, Darzalex, Tecvayli |
| Beone Medicines USA, INC. | $125.00 | 2025 | Brukinsa |
| Biohaven Pharmaceutical Holding Company LTD. | $116.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $110.12 | 2022-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $100.45 | 2023-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $90.55 | 2019 | |
| Horizon Therapeutics Plc | $90.39 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $88.43 | 2024-2025 | Voquezna |
| Eisai INC. | $84.72 | 2020-2021 | |
| Medline Industries LP | $82.66 | 2019 | |
| Mylan Specialty L.P. | $77.91 | 2019-2023 | Yupelri |
| Corium, LLC | $66.19 | 2022-2023 | Adlarity |
| Boston Scientific Corporation | $62.02 | 2023-2025 | Watchman Flx, General - Pain Management |
| Arbor Pharmaceuticals, INC. | $59.47 | 2019-2021 | |
| Daiichi Sankyo INC. | $54.51 | 2023-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $45.64 | 2022-2024 | Eliquis |
| Allergan, INC. | $44.62 | 2019-2020 | |
| Ibsa Pharma INC. | $44.31 | 2020-2023 | Tirosint, Licart |
| Corcept Therapeutics | $36.89 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $35.91 | 2021-2025 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $35.23 | 2021 | |
| Neurocrine Biosciences, INC. | $33.18 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.36 | 2019-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $27.54 | 2022 | |
| Insmed, INC. | $27.24 | 2025 | Arikayce |
| Nevro Corp. | $25.45 | 2023 | Senza |
| Hikma Pharmaceuticals USA | $18.36 | 2019 | |
| Cipher Pharmaceuticals US LLC | $14.76 | 2025 | Natroba, Spinosad |
| Sanofi Pasteur INC. | $13.66 | 2021 | |
| Biogen, INC. | $13.37 | 2022 | |
| Currax Pharmaceuticals LLC | $12.78 | 2021 | |
| Antares Pharma, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Boykin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.